Chinese biopharmaceutical companies witnessed a robust rally in Hong Kong on Monday, with shares soaring after reports indicated that the U.S. is contemplating rules that would largely allow American pharmaceutical giants to continue licensing drug deals with Chinese counterparts.
This potential easing of restrictions sparked significant investor optimism. Innovent Biologics saw its shares jump by 6%, while Akeso surged an impressive 8%. Other notable gainers included CSPC Pharmaceutical Group, which climbed over 6%, HUTCHMED, up 3%, and Sino Biopharmaceutical, adding 8%. The broader Hang Seng Biotech Index mirrored this positive sentiment, advancing more than 5%.
The market's reaction follows a Friday report from Reuters, citing sources familiar with the discussions, detailing that the U.S. Treasury Department is in the process of drafting regulations. These rules are expected to permit American pharmaceutical firms to invest in promising new drugs being developed by Chinese companies, with exceptions primarily for technologies related to pathogens or biotechnology that could potentially be weaponized. It's crucial to note that these rules are not yet finalized and are subject to change.
This proposed framework would set the biopharma sector on a distinct path compared to other high-tech industries like artificial intelligence and semiconductors, where the U.S. has increasingly tightened restrictions on China. This suggests a strategic differentiation in Washington's approach to critical sectors involving China.
A young female worker in protective gear carefully carries a container filled with blister-packaged capsules, a crucial step in the transportation process of pharmaceutical products. Showcasing the importance of safety and attention to detail in the industry.
Extreme Media | E+ | Getty Images
Cross-border licensing deals have been a significant growth driver. According to GlobalData, almost half of U.S. drug licensing agreements with overseas firms in 2025 involved Chinese companies. This trend underscores the importance of Chinese innovation in the global pharmaceutical landscape.
Major pharmaceutical players have already engaged in substantial collaborations. For instance, Pfizer announced a partnership with Innovent in May, valued at up to $10.5 billion, focusing on the research and development of 12 oncology programs.
Despite geopolitical tensions, China's out-licensing sector has boomed, with a record 81 deals totaling $110 billion completed in the first half of 2026, according to NMPA data cited by Nomura. Analysts from Nomura suggest that investors have become "largely immune" to intermittent geopolitical concerns due to the strong value proposition offered by Chinese companies in novel drug development.
Furthermore, China's 15th five-year plan identifies globalization as a key objective for its pharmaceutical and biotech firms. Against this strategic backdrop, Nomura anticipates that China-U.S. out-licensing deals are poised to continue their strong upward trajectory.
